Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

Abstract

Companion diagnostics (CDx) plays a pivotal role in precision medicine by enabling personalized treatment plans based on individual biomarker profiles. This approach can enhance therapeutic efficacy in selected indications and may reduce healthcare expenditures. Particularly in oncology, precision targeted therapies targeting pathways such as EGFR, HER2, and programmed death-1/programmed death-ligand 1 have established robust models for biomarker-driven treatment. However, rapid advancements in diagnostic technologies, expanding application scopes, and increasingly complex mechanisms of biomarker resistance are presenting new challenges for CDx. This review comprehensively examines the evolving regulatory landscape, current clinical applications across various solid tumors and hematologic malignancies, and diverse methodological platforms ranging from next-generation sequencing and immunohistochemistry to emerging liquid biopsies and point-of-care testing. It also delves into persistent barriers in CDx development, including tumor heterogeneity, test standardization, trade-offs between tissue biopsy and liquid biopsy, and the economic complexities of codevelopment and reimbursement mechanisms. By synthesizing existing knowledge and projecting future trends, this paper serves as a valuable resource for researchers, regulators, and clinicians. It provides critical insights to guide the synergistic development of drugs and diagnostics, paving the way for their integration into a more dynamic, artificial intelligence-enhanced, and multiomics-driven healthcare ecosystem.

Keywords

companion diagnostics / in vitro diagnostics / next-generation sequencing / oncology treatment / personalized medicine / precision medicine

References

[1] F. Beccia, I. Hoxhaj, C. Castagna, et al., “An Overview of Personalized Medicine Landscape and Policies in the European Union,” European Journal of Public Health 32, no. 6 (2022): 844–851.

[2] O. Strianese, F. Rizzo, M. Ciccarelli, et al., “Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease,” Genes 11, no. 7 (2020): 747.

[3] G. M. Sprinzl and A. Magele, “Personalized Medicine in Otolaryngology: Special Topic Otology,” Journal of Personalized Medicine 12, no. 11 (2022): 1820.

[4] S. Kunte, J. Abraham, and A. J. Montero, “Novel HER2-targeted Therapies for HER2-positive Metastatic Breast Cancer,” Cancer 126, no. 19 (2020): 4278–4288.

[5] J. T. Jørgensen and J. Mollerup, “Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC,” Cancers (Basel) 14, no. 9 (2022): 2150.

[6] V. Valla, S. Alzabin, A. Koukoura, et al., “Companion Diagnostics: State of the Art and New Regulations,” Biomarker Insights 16 (2021): 11772719211047763.

[7] E. Csoke, S. Landes, M. J. Francis, et al., “How Can Real-world Evidence Aid Decision Making during the Life Cycle of Nonprescription Medicines?,” Clinical and Translational Science 15, no. 1 (2022): 43–54.

[8] C. P. Milne, C. Bryan, S. Garafalo, et al., “Complementary versus Companion Diagnostics: Apples and Oranges?,” Biomarkers in Medicine 9, no. 1 (2015): 25–34.

[9] J. J. Gao, C. L. Osgood, Y. Gong, et al., “FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients With HER2-positive Breast Cancer,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 27, no. 8 (2021): 2126–2129.

[10] T. Phillips, M. M. Millett, X. Zhang, et al., “Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma,” Applied Immunohistochemistry & Molecular Morphology: AIMM 26, no. 1 (2018): 6–12.

[11] J. T. Jørgensen, “Companion and Complementary Diagnostics: An Important Treatment Decision Tool in Precision Medicine,” Expert Review of Molecular Diagnostics 20, no. 6 (2020): 557–559.

[12] J. C. Stingl, “Pharmacogenetic Biomarkers for Companion and Complementary Diagnostics: Challenges for Clinical Practice and Regulation,” Expert Review of Precision Medicine and Drug Development 1, no. 5 (2016): 415–418.

[13] H. Scheerens, A. Malong, K. Bassett, et al., “Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch,” Clinical and Translational Science 10, no. 2 (2017): 84–92.

[14] H. Hampel, P. Gao, J. Cummings, et al., “The Foundation and Architecture of Precision Medicine in Neurology and Psychiatry,” Trends in Neurosciences 46, no. 3 (2023): 176–198.

[15] A. A. Baumann, Z. Buribayev, O. Wolkenhauer, et al., “Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse,” Epigenomes 9, no. 1 (2025): 5.

[16] K. T. Schmidt, C. H. Chau, D. K. Price, et al., “Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment,” Journal of Clinical Pharmacology 56, no. 12 (2016): 1484–1499.

[17] P. Keeling, J. Clark, and S. Finucane, “Challenges in the Clinical Implementation of Precision Medicine Companion Diagnostics,” Expert Review of Molecular Diagnostics 20, no. 6 (2020): 593–599.

[18] T. B. G. Poulsen, A. Karamehmedovic, C. Aboo, et al., “Protein Array-based Companion Diagnostics in Precision Medicine,” Expert Review of Molecular Diagnostics 20, no. 12 (2020): 1183–1198.

[19] M. R. Campbell, “Update on Molecular Companion Diagnostics—A Future in Personalized Medicine Beyond Sanger Sequencing,” Expert Review of Molecular Diagnostics 20, no. 6 (2020): 637–644.

[20] N. Papadopoulos, K. W. Kinzler, and B. Vogelstein, “The Role of Companion Diagnostics in The Development and Use of Mutation-Targeted Cancer Terapies,” Nature biotechnology 24, no. 8 (2006): 985–995.

[21] I. A. Cree, “Diagnostic Ras Mutation Analysis by Polymerase Chain Reaction (PCR),” Biomolecular Detection and Quantification 8 (2016): 29–32.

[22] J. T. Jørgensen, “Clinical Application of Companion Diagnostics,” Trends in Molecular Medicine 21, no. 7 (2015): 405–407.

[23] M. Kaufmann, M. Keppens, and E. D. Blair, “A Perspective Analysis: Companion Diagnostics: An Evolving Paradigm in 21st Century Healthcare,” Personalized Medicine 12, no. 4 (2015): 389–402.

[24] J. T. Jørgensen, “A Changing Landscape for Companion Diagnostics,” Expert Review of Molecular Diagnostics 13, no. 7 (2013): 667–669.

[25] Y. Hu, Y. Sun, Q. H. Zhu, et al., “Poaceae Chloroplast Genome Sequencing: Great Leap Forward in Recent Ten Years,” Current Genomics 23, no. 6 (2023): 369–384.

[26] T. C. Chou, L. You, C. Beerens, et al., “Instant Processing of Large-scale Image Data With FACT, a Real-time Cell Segmentation and Tracking Algorithm,” Cell Reports Methods 3, no. 11 (2023): 100636.

[27] H. Li, S. E. Huang, C. L. Geng, et al., “Comprehensive Analysis Reveals Hub Genes Associated With Immune Cell Infiltration in Allergic Rhinitis,” World Journal of Otorhinolaryngology—Head and Neck Surgery 9, no. 4 (2023): 340–351.

[28] D. Olsen and J. T. Jørgensen, “Companion Diagnostics for Targeted Cancer Drugs—Clinical and Regulatory Aspects,” Frontiers in Oncology 4 (2014): 105.

[29] FDA. Companion Diagnostics 2023, https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics.

[30] FDA. Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program 2023, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-drug-products-used-certain-in-vitro-diagnostic-tests-pilot-program.

[31] F. Pignatti, F. Ehmann, R. Hemmings, et al., “Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20, no. 6 (2014): 1458–1468.

[32] L. P. Orellana García, F. Ehmann, and P. A. Hines, “Biomarker and Companion Diagnostics-A Review of Medicinal Products Approved by the European Medicines Agency,” Frontiers in Medicine 8 (2021): 753187.

[33] V. Wurcel, O. Perche, D. Lesteven, et al., “The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care Into an Affordable Reality in Europe,” Public Health Genomics 19, no. 3 (2016): 137–143.

[34] A. M. Senderowicz and O. Pfaff, “Similarities and Differences in the Oncology Drug Approval Process Between FDA and European Union With Emphasis on in Vitro Companion Diagnostics,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20, no. 6 (2014): 1445–1452.

[35] K. S. Oliner, M. Shiller, P. Schmid, et al., “Challenges to Innovation Arising From Current Companion Diagnostic Regulations and Suggestions for Improvements,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 31, no. 5 (2025): 795–800.

[36] E. Y. Lee and H. C. Shen, “Regulatory Considerations for Companion Diagnostic Devices,” Biomarkers in Medicine 9, no. 1 (2015): 67–75.

[37] T. Golan, M. Milella, A. Ackerstein, et al., “The Changing Face of Clinical Trials in the Personalized Medicine and Immuno-oncology Era: Report From the International Congress on Clinical Trials in Oncology & Hemato-Oncology (ICTO 2017),” Journal of Experimental & Clinical Cancer Research 36, no. 1 (2017): 192.

[38] M. Li, “Statistical Consideration and Challenges in Bridging Study of Personalized Medicine,” Journal of Biopharmaceutical Statistics 25, no. 3 (2015): 397–407.

[39] J. T. Jørgensen, S. Møller, B. B. Rasmussen, et al., “High Concordance Between Two Companion Diagnostics Tests: A Concordance Study Between the HercepTest and the HER2 FISH PharmDx Kit,” American Journal of Clinical Pathology 136, no. 1 (2011): 145–151.

[40] A. Ritzhaupt, I. Hayes, and F. Ehmann, “Implementing the EU in Vitro Diagnostic Regulation—A European Regulatory Perspective on Companion Diagnostics,” Expert Review of Molecular Diagnostics 20, no. 6 (2020): 565–567.

[41] EMA. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (Text with EEA relevance.) 2017, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0746.

[42] (MFDS) MoFaDS. Act on In Vitro Diagnostic Medical Devices Sejong, Korea 2020, https://www.mfds.go.kr/eng/brd/m_75/view.do?company_cd&company_nm&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&page=1&seq=4&srchFr&srchTo&srchTp&srchWord&utm_source=chatgpt.com.

[43] Japan Go. Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices Tokyo (Japan: Japanese Law Translation, 2014), https://www.japaneselawtranslation.go.jp/en/laws/view/3213/en.

[44] A. Tanaka, H. Suzuki, S. Toyoshima, et al., “Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan,” Therapeutic Innovation & Regulatory Science 56, no. 1 (2022): 85–95.

[45] P. Kukk, E. H. M. Moors, and M. P. Hekkert, “The Complexities in System Building Strategies—The Case of Personalized Cancer Medicines in England,” Technological Forecasting and Social Change 98 (2015): 47–59.

[46] C. G. Ferreira, M. I. Achatz, P. Ashton-Prolla, et al., “Brazilian Health-care Policy for Targeted Oncology Therapies and Companion Diagnostic Testing,” The Lancet Oncology 17, no. 8 (2016): e363–e370.

[47] K. Mistry, S. Sadarangani, D. Moreno, et al., “Novel Biomarkers and Imaging Tests for Acute Kidney Injury Diagnosis in Patients With Cancer,” Kidney360 6, no. 1 (2025): 167–174.

[48] S. Cheng, W. H. Koch, and L. Wu, “Co-development of a Companion Diagnostic for Targeted Cancer Therapy,” New Biotechnology 29, no. 6 (2012): 682–688.

[49] M. S. Boguski and M. W. McIntosh, “Biomedical Informatics for Proteomics,” Nature 422, no. 6928 (2003): 233–237.

[50] M. W. Moore, D. Babu, and P. D. Cotter, “Challenges in the Codevelopment of Companion Diagnostics,” Personalized Medicine 9, no. 5 (2012): 485–496.

[51] A. Ocana, J. L. Ethier, L. Díez-González, et al., “Influence of Companion Diagnostics on Efficacy and Safety of Targeted Anti-cancer Drugs: Systematic Review and Meta-Analyses,” Oncotarget 6, no. 37 (2015): 39538–39549.

[52] J. T. Jørgensen, “Companion Diagnostics: The Key to Personalized Medicine. Foreword,” Expert Review of Molecular Diagnostics 15, no. 2 (2015): 153–156.

[53] C. Schmidt, “Challenges Ahead for Companion Diagnostics,” Journal of the National Cancer Institute 104, no. 1 (2012): 14–15.

[54] Y. S. Fan, “Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview,” Genetic Testing and Molecular Biomarkers 17, no. 7 (2013): 515–523.

[55] D. A. Murphy, H. A. Ely, R. Shoemaker, et al., “Detecting Gene Rearrangements in Patient Populations through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing,” Applied Immunohistochemistry & Molecular Morphology: AIMM 25, no. 7 (2017): 513–523.

[56] R. Tenchov, A. K. Sapra, J. Sasso, et al., “Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers,” ACS Pharmacol Transl Sci 7, no. 3 (2024): 586–613.

[57] N. Nevler, D. Niehoff, A. M. Gleixner, et al., “Developing Digital Health Technologies for Frontotemporal Degeneration,” Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21, no. 4 (2025): e70082.

[58] H. C. Wang, T. J. Yeh, L. P. Chan, et al., “Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice,” International Journal of Molecular Sciences 21, no. 20 (2020): 7621.

[59] R. Simon, “Sensitivity, Specificity, PPV, and NPV for Predictive Biomarkers,” Journal of the National Cancer Institute 107, no. 8 (2015): djv153.

[60] S. Liao, M. Zhou, Y. Wang, et al., “Emerging Biomedical Imaging-based Companion Diagnostics for Precision Medicine,” iScience 26, no. 8 (2023): 107277.

[61] C. Huber, T. Friede, J. Stingl, et al., “Classification of Companion Diagnostics: A New Framework for Biomarker-Driven Patient Selection,” Therapeutic Innovation & Regulatory Science 56, no. 2 (2022): 244–254.

[62] B. J. Min, W. S. Lee, M. E. Seo, et al., “Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients With Solid Tumors,” Cancers (Basel) 13, no. 20 (2021): 5112.

[63] D. E. Carvajal-Hausdorf, K. A. Schalper, V. M. Neumeister, et al., “Quantitative Measurement of Cancer Tissue Biomarkers in the Lab and in the Clinic,” Laboratory Investigation; A Journal of Technical Methods and Pathology 95, no. 4 (2015): 385–396.

[64] Y. Cao, R. Agarwal, F. Dituri, et al., “NGS-based Transcriptome Profiling Reveals Biomarkers for Companion Diagnostics of the TGF-β Receptor Blocker Galunisertib in HCC,” Cell Death & Disease 8, no. 2 (2017): e2634.

[65] E. Conde, S. Hernandez, M. Prieto, et al., “Profile of Ventana ALK (D5F3) Companion Diagnostic Assay for Non-small-cell Lung Carcinomas,” Expert Review of Molecular Diagnostics 16, no. 6 (2016): 707–713.

[66] N. B. La Thangue and D. J. Kerr, “Predictive Biomarkers: A Paradigm Shift towards Personalized Cancer Medicine,” Nature Reviews Clinical Oncology 8, no. 10 (2011): 587–596.

[67] I. A. Cree, “Progress and Potential of RAS Mutation Detection for Diagnostics and Companion Diagnostics,” Expert Review of Molecular Diagnostics 16, no. 10 (2016): 1067–1072.

[68] T. A. Yap, S. K. Sandhu, P. Workman, et al., “Envisioning the Future of Early Anticancer Drug Development,” Nature Reviews Cancer 10, no. 7 (2010): 514–523.

[69] V. S. Nikam. Companion Diagnostics and Clinical Biomarkers for Immunotherapy. in Immunotherapy – A Novel Facet of Modern Therapeutics, ed. S. P. Sawarkar, V. S. Nikam, and S. Syed (Singapore: Springer Singapore, 2021): 137–152.

[70] A. Tibau, L. Díez-González, B. Navarro, et al., “Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs,” Molecular Diagnosis & Therapy 21, no. 3 (2017): 337–343.

[71] D. R. Parkinson, B. E. Johnson, and G. W. Sledge, “Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18, no. 3 (2012): 619–624.

[72] M. K. Le, N. Oishi, K. Mochizuki, et al., “Immunohistochemical Detection of Cancer Genetic Abnormalities,” Pathology, Research and Practice 255 (2024): 155109.

[73] L. Hu, K. Ru, L. Zhang, et al., “Fluorescence in Situ Hybridization (FISH): An Increasingly Demanded Tool for Biomarker Research and Personalized Medicine,” Biomarker Research 2, no. 1 (2014): 3.

[74] J. Ma, N. Li, M. Guarnera, et al., “Quantification of Plasma miRNAs by Digital PCR for Cancer Diagnosis,” Biomarker Insights 8 (2013): 127–136.

[75] M. Chen and H. Zhao, “Next-generation Sequencing in Liquid Biopsy: Cancer Screening and Early Detection,” Human Genomics 13, no. 1 (2019): 34.

[76] R. A. Joy, S. K. Thelakkattusserry, N. Vikkath, et al., “Somatic Mutation Detection Efficiency in EGFR: A Comparison Between High Resolution Melting Analysis and Sanger Sequencing,” BMC Cancer 20, no. 1 (2020): 902.

[77] M. Hussain, N. Mackrides, S. Su, et al., “A Case Report of Concurrent Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719A) and Exon 21 (L833_V834delinsFL) Mutations and Treatment Challenges,” Cureus 16, no. 10 (2024): e70896.

[78] Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee, & Anti-cancer Drug Safety Management Committee (ASMC). Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC (2022 Version). Zhongguo Fei Ai Za Zhi 2022; 25(9): 627–641.

[79] S. Y. Sun, “Taking Early Preventive Interventions to Manage the Challenging Issue of Acquired Resistance to Third-generation EGFR Inhibitors,” Chin Med J Pulm Crit Care Med 1, no. 1 (2023): 3–10.

[80] Y. Li, J. Luo, W. Yip, et al., “P3.02-062 An EGFR Follow-On Companion Diagnostic for Clinical Care of Patients With NSCLC,” Journal of Thoracic Oncology 12, no. 11 (2017): S2260.

[81] T. Jatkoe, S. Wang, J. I. Odegaard, et al., “Clinical Validation of Companion Diagnostics for the Selection of Patients With Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment With Amivantamab,” The Journal of Molecular Diagnostics: JMD 24, no. 11 (2022): 1181–1188.

[82] A. Inoue, K. Kobayashi, M. Maemondo, et al., “Updated Overall Survival Results From a Randomized Phase III Trial Comparing Gefitinib With Carboplatin-paclitaxel for Chemo-naïve Non-small Cell Lung Cancer With Sensitive EGFR Gene Mutations (NEJ002),” Annals of Oncology: Official Journal of the European Society for Medical Oncology 24, no. 1 (2013): 54–59.

[83] G. Zhang, B. Yan, Y. Guo, et al., “Case Report: A Patient With the Rare Third-generation TKI-resistant Mutation EGFR L718Q Who Responded to Afatinib Plus Cetuximab Combination Therapy,” Frontiers in Oncology 12 (2022): 995624.

[84] Z. Liang, Y. Cheng, Y. Chen, et al., “EGFR T790M ctDNA Testing Platforms and Their Role as Companion Diagnostics: Correlation With Clinical Outcomes to EGFR-TKIs,” Cancer Letters 403 (2017): 186–194.

[85] C. Zhou, Y. L. Wu, G. Chen, et al., “Erlotinib versus Chemotherapy as First-line Treatment for Patients With Advanced EGFR Mutation-positive Non-small-cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-label, Randomised, Phase 3 Study,” The Lancet Oncology 12, no. 8 (2011): 735–742.

[86] Y. L. Wu, C. Zhou, C. P. Hu, et al., “Afatinib ersus Cisplatin Plus Gemcitabine for First-line Treatment of Asian Patients With Advanced Non-small-cell Lung Cancer Harbouring EGFR Mutations (LUX-Lung 6): An Open-label, Randomised Phase 3 Trial,” The Lancet Oncology 15, no. 2 (2014): 213–222.

[87] J. C. Soria, Y. Ohe, J. Vansteenkiste, et al., “Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer,” New England Journal of Medicine 378, no. 2 (2018): 113–125.

[88] S. Hagan, M. C. Orr, and B. Doyle, “Targeted Therapies in Colorectal Cancer-an Integrative View by PPPM,” Epma J 4, no. 1 (2013): 3.

[89] K. Y. Chung, J. Shia, N. E. Kemeny, et al., “Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry,” Journal of Clinical Oncology 23, no. 9 (2005): 1803–1810.

[90] N. Karachaliou and R. Rosell, “Targeted Treatment of Mutated EGFR-expressing Non-small-cell Lung Cancer: Focus on Erlotinib With Companion Diagnostics,” Lung Cancer (Auckl) 5 (2014): 73–79.

[91] S. Benlloch, M. L. Botero, J. Beltran-Alamillo, et al., “Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non-small-cell Lung Cancer: Retrospective Testing of Specimens From the EURTAC Ttrial,” PLoS ONE 9, no. 2 (2014): e89518.

[92] G. Goss, C. M. Tsai, F. A. Shepherd, et al., “Osimertinib for Pretreated EGFR Thr790Met-positive Advanced Non-small-cell Lung Cancer (AURA2): A Multicentre, Open-label, Single-arm, Phase 2 Study,” The Lancet Oncology 17, no. 12 (2016): 1643–1652.

[93] K. Uchibori, N. Takano, R. Manabe, et al., “Clinical Influence of Switching Companion Diagnostic Tests for EGFR-TKs From Therascreen to Cobas V2,” Thoracic Cancer 12, no. 6 (2021): 906–913.

[94] C. J. Robbins, K. M. Bates, and D. L. Rimm, “HER2 Testing: Evolution and Update for a Companion Diagnostic Assay,” Nature Reviews Clinical Oncology 22, no. 6 (2025): 408–423.

[95] J. T. Jørgensen, H. Winther, J. Askaa, et al., “A Companion Diagnostic with Significant Clinical Impact in Treatment of Breast and Gastric Cancer,” Frontiers in Oncology 11 (2021): 676939.

[96] U. F. Vogel, “Confirmation of a Low HER2 Positivity Rate of Breast Carcinomas—Limitations of Immunohistochemistry and in Situ Hybridization,” Diagn Pathol 5 (2010): 50.

[97] D. Cameron, M. J. Piccart-Gebhart, R. D. Gelber, et al., “11 Years' Follow-up of Trastuzumab After Adjuvant Chemotherapy in HER2-positive Early Breast Cancer: Final Analysis of the HERceptin Adjuvant (HERA) Trial,” Lancet 389, no. 10075 (2017): 1195–1205.

[98] C. Keckeisen, A. Šujanová, T. Himmel, et al., “Isospora and Lankesterella Parasites (Eimeriidae, Apicomplexa) of Passeriform Birds in Europe: Infection Rates, Phylogeny, and Pathogenicity,” Pathogens 13, no. 4 (2024): 337.

[99] L. R. Grazziotin, B. R. Dada, C. de la Rosa Jaimes, et al., “Chromogenic and Silver in Situ Hybridization for Identification of HER2 Overexpression in Breast Cancer Patients: A Systematic Review and Meta-Analysis,” Applied Immunohistochemistry & Molecular Morphology: AIMM 28, no. 6 (2020): 411–421.

[100] A. Cayre, F. Mishellany, N. Lagarde, et al., “Comparison of Different Commercial Kits for HER2 Testing in Breast Cancer: Looking for the Accurate Cutoff for Amplification,” Breast Cancer Research 9, no. 5 (2007): R64.

[101] A. Dilawari, H. Zhang, M. Shah, et al., “US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients with Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer,” Journal of Clinical Oncology 43, no. 26 (2025): 2942–2951.

[102] J. Kim, H. S. Kim, M. Nam, et al., “Tissue-Agnostic Biomarkers in Solid Tumors: Current Approvals and Emerging Candidates,” Cancer and Metastasis Reviews 44, no. 3 (2025): 58.

[103] F. Meric-Bernstam, V. Makker, A. Oaknin, et al., “Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results from the DESTINY-PanTumor02 Phase II Trial,” Journal of Clinical Oncology 42, no. 1 (2024): 47–58.

[104] C. Yoo and Y. S. Park, “Companion Diagnostics for the Targeted Therapy of Gastric Cancer,” World Journal of Gastroenterology 21, no. 39 (2015): 10948–10955.

[105] J. J. Harding, J. Fan, D. Y. Oh, et al., “Zanidatamab for HER2-amplified, Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer (HERIZON-BTC-01): A Multicentre, Single-arm, Phase 2b Study,” The Lancet Oncology 24, no. 7 (2023): 772–782.

[106] M. Yi, X. Zheng, M. Niu, et al., “Combination Strategies With PD-1/PD-L1 Blockade: Current Advances and Future Directions,” Molecular Cancer 21, no. 1 (2022): 28.

[107] A. A. Davis and V. G. Patel, “The Role of PD-L1 Expression as a Predictive Biomarker: An Analysis of all US Food and Drug Administration (FDA) Approvals of Immune Checkpoint Inhibitors,” Journal for Immunotherapy of Cancer 7, no. 1 (2019): 278.

[108] D. B. Doroshow, S. Bhalla, M. B. Beasley, et al., “PD-L1 as a Biomarker of Response to Immune-checkpoint Inhibitors,” Nature Reviews Clinical Oncology 18, no. 6 (2021): 345–362.

[109] D. Kazandjian, D. L. Suzman, G. Blumenthal, et al., “FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer with Progression on or after Platinum-Based Chemotherapy,” The Oncologist 21, no. 5 (2016): 634–642.

[110] J. Sul, G. M. Blumenthal, X. Jiang, et al., “FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Express Programmed Death-Ligand 1,” The Oncologist 21, no. 5 (2016): 643–650.

[111] M. Skrzypski and J. Jassem, “Consolidation Systemic Treatment After Radiochemotherapy for Unresectable Stage III Non-small Cell Lung Cancer,” Cancer Treatment Reviews 66 (2018): 114–121.

[112] F. Ohyanagi, M. Nomura, J. Shiihara, et al., “P37.08 OncomineTM Dx Target Test Companion Diagnostic System for Advanced Non-Small Cell Lung Cancer,” Journal of Thoracic Oncology 16, no. 3 (2021): S445.

[113] S. Marwitz, S. Scheufele, S. Perner, et al., “Epigenetic Modifications of the Immune-checkpoint Genes CTLA4 and PDCD1 in Non-small Cell Lung Cancer Results in Increased Expression,” Clinical Epigenetics 9 (2017): 51.

[114] M. Hersom and J. T. Jørgensen, “Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer,” Therapeutic Drug Monitoring 40, no. 1 (2018): 9–16.

[115] J. T. Jørgensen, “Companion Diagnostic Assays for PD-1/PD-L1 Checkpoint Inhibitors in NSCLC,” Expert Review of Molecular Diagnostics 16, no. 2 (2016): 131–133.

[116] M. Rebelatto, A. Mistry, C. Sabalos, et al., “Development of a PD-L1 Companion Diagnostic Assay for Treatment With MEDI4736 in NSCLC and SCCHN Patients,” Journal of Clinical Oncology 33, no. 15 (2015): 8033–8033.

[117] A. Dimou, K. Harrington, and K. N. Syrigos, “From the Bench to Bedside: Biological and Methodology Considerations for the Future of Companion Diagnostics in Nonsmall Cell Lung Cancer,” Pathology Research International 2011 (2011): 312346.

[118] M. Moutafi and D. L. Rimm, “Putting the Microenvironment Into the Immunotherapy Companion Diagnostic,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 27, no. 14 (2021): 3812–3814.

[119] J. Caldara, J. S. Krueger, E. Ergon, et al., “Abstract 4923: Analysis of Companion Diagnostic Potentials for Multifaceted PD-L1 Assays,” Cancer Research 79, no. 13 (2019): 4923–4923.

[120] E. Chang, L. Pelosof, S. Lemery, et al., “Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health,” The Oncologist 26, no. 10 (2021): e1786–e1799.

[121] M. Dolled-Filhart, C. Roach, G. Toland, et al., “Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1,” Archives of Pathology & Laboratory Medicine 140, no. 11 (2016): 1243–1249.

[122] W. T. Huang, T. Yun, C. H. Chew, et al., “Microtube Array Membrane Hollow Fiber Assay (MTAM-HFA)-An Accurate and Rapid Potential Companion Diagnostic and Pharmacological Interrogation Solution for Cancer Immunotherapy (PD-1/PD-L1),” Biomolecules 12, no. 4 (2022): 480.

[123] A. R. Hansen and L. L. Siu, “PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development,” JAMA Oncology 2, no. 1 (2016): 15–16.

[124] D. L. Rimm, G. Han, J. M. Taube, et al., “Reanalysis of the NCCN PD-L1 Companion Diagnostic Assay Study for Lung Cancer in the Context of PD-L1 Expression Findings in Triple-negative Breast Cancer,” Breast Cancer Research 21, no. 1 (2019): 72.

[125] K. Mizutani, K. Horie, T. Kato, et al., “Serum PD-1 Levels Measured by ELISA Using Nivolumab Increased in Advanced RCC Patients: Novel Approach to Develop Companion Diagnostics for Antibody Therapy,” Journal of Cancer Research and Clinical Oncology 145, no. 6 (2019): 1661–1663.

[126] D. König, S. Savic Prince, and S. I. Rothschild, “Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations,” Cancers (Basel) 13, no. 4 (2021): 804.

[127] R. C. Maloney, M. Zhang, H. Jang, et al., “The Mechanism of Activation of Monomeric B-RAF V600E,” Computational and Structural Biotechnology Journal 19 (2021): 3349–3363.

[128] R. Langland, T. Sharp, J. Tsai, et al., “Development of a Companion Diagnostic Test for Inhibitors of V600E BRAF,” Clinical Cancer Research 12, no. 19_Supplement (2014): A13–A13.

[129] H. Halait, K. Demartin, S. Shah, et al., “Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma,” Diagnostic Molecular Pathology: The American Journal of Surgical Pathology, Part B 21, no. 1 (2012): 1–8.

[130] F. Lopez-Rios, B. Angulo, B. Gomez, et al., “Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-approval Validation Study of the Companion Diagnostic Test for Vemurafenib,” PLoS ONE 8, no. 1 (2013): e53733.

[131] L. Huang, C. Wen, X. Yang, et al., “PEAK1, Acting as a Tumor Promoter in Colorectal Cancer, Is Regulated by the EGFR/KRas Signaling Axis and miR-181d,” Cell Death & Disease 9, no. 3 (2018): 271.

[132] J. M. Bauml, B. T. Li, V. Velcheti, et al., “Clinical Validation of Guardant360 CDx as a Blood-based Companion Diagnostic for Sotorasib,” Lung Cancer (Amsterdam, Netherlands) 166 (2022): 270–278.

[133] O. O'Brien, M. C. Wright, and C. O'Brien, “Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples,” Diagnostics (Basel) 9, no. 1 (2019): 13.

[134] G. R. Oxnard, J. C. Yang, H. Yu, et al., “TATTON: A Multi-arm, Phase Ib Trial of Osimertinib Combined With Selumetinib, Savolitinib, or Durvalumab in EGFR-mutant Lung Cancer,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 31, no. 4 (2020): 507–516.

[135] M. Schuler, R. Berardi, W. T. Lim, et al., “Molecular Correlates of Response to Capmatinib in Advanced Non-small-cell Lung Cancer: Clinical and Biomarker Results From a Phase I Trial,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 31, no. 6 (2020): 789–797.

[136] S. M. Wu, W. S. Tsai, S. F. Chiang, et al., “Comprehensive Transcriptome Profiling of Taiwanese Colorectal Cancer Implicates an Ethnic Basis for Pathogenesis,” Scientific Reports 10, no. 1 (2020): 4526.

[137] S. Kang, J. Woo, and S. Kim, “A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer,” Diagnostics (Basel) 12, no. 5 (2022): 1297.

[138] K. Takeuchi, Y. Togashi, Y. Kamihara, et al., “Prospective and Clinical Validation of ALK Immunohistochemistry: Results From the Phase I/II Study of Alectinib for ALK-positive Lung Cancer (AF-001JP study),” Annals of Oncology: Official Journal of the European Society for Medical Oncology 27, no. 1 (2016): 185–192.

[139] L. Nguyen, W. M. Martens J, A. Van Hoeck, et al., “Pan-cancer Landscape of Homologous Recombination Deficiency,” Nature Communications 11, no. 1 (2020): 5584.

[140] C. J. LaFargue, G. Z. Dal Molin, A. K. Sood, et al., “Exploring and Comparing Adverse Events Between PARP Inhibitors,” The Lancet Oncology 20, no. 1 (2019): e15–e28.

[141] L. E. Dockery, C. C. Gunderson, and K. N. Moore, “Rucaparib: The Past, Present, and Future of a Newly Approved PARP Inhibitor for Ovarian Cancer,” OncoTargets and Therapy 10 (2017): 3029–3037.

[142] C. C. Gunderson and K. N. Moore, “BRACAnalysis CDx as a Companion Diagnostic Tool for Lynparza,” Expert Review of Molecular Diagnostics 15, no. 9 (2015): 1111–1116.

[143] S. Dunn, “Dr Sandi Dunn Illuminates Emerging Key Treatment Approaches and Companion Diagnostics for Triple Negative Breast Cancer,” Expert Opinion on Investigational Drugs 29, no. 12 (2020): 1309–1312.

[144] T. Golan, P. Hammel, M. Reni, et al., “Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer,” New England Journal of Medicine 381, no. 4 (2019): 317–327.

[145] J. de Bono, J. Mateo, and K. Fizazi, “Olaparib for Metastatic Castration-Resistant Prostate Cancer,” New England Journal of Medicine 382, no. 22 (2020): 2091–2102.

[146] V. Kumar, J. Yu, V. Phan, et al., “Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer,” JCO Precision Oncology 1 (2017): 1–19.

[147] Y. Kimura, T. Itagaki, and M. Ohara, “Companion Diagnosis by BRACAnalysis CDx^TM and Therapeutic Experience of Olaparib for HER2-negative Breast Cancer,” Annals of Oncology 30 (2019): vi136.

[148] J. S. Kwon, A. V. Tinker, A. Karsan, et al., “Costs and Benefits of Tumor Testing for Mutations in High-grade Serous Ovarian Cancer as a Companion Diagnostic for PARP Inhibitor Treatment,” Gynecologic Oncology 154 (2019): 177–177.

[149] F. Sotgia and M. P. Lisanti, “Mitochondrial mRNA Transcripts Predict Overall Survival, Tumor Recurrence and Progression in Serous Ovarian Cancer: Companion Diagnostics for Cancer Therapy,” Oncotarget 8, no. 40 (2017): 66925–66939.

[150] K. L. Copeland, S. B. Wehnelt, L. E. Wange, et al., “Outcomes of Clinical Testing for Tumor BRAC1 and BRCA2 Gene Analysis for 354 Patients: First Experience With Tumor Companion Diagnostic for PARP Inhibitors,” Annals of Oncology 27 (2016): vi301.

[151] T. Takeda, K. Tsuji, Y. Kobayashi, et al., “Clinical and Pathological Analysis of Companion Diagnostic Testing of Microsatellite Instability-high for Pembrolizumab in Gynaecologic Malignancy,” Japanese Journal of Clinical Oncology 52, no. 2 (2022): 128–133.

[152] L. Serpe, M. Gallicchio, R. Canaparo, et al., “Targeted Treatment of Folate Receptor-positive Platinum-resistant Ovarian Cancer and Companion Diagnostics, With Specific Focus on Vintafolide and Etarfolatide,” Pharmacogenomics and Personalized Medicine 7 (2014): 31–42.

[153] D. Mancini-DiNardo and K. Brown, “Precision Medicine and Companion Diagnostics Join the Battle against Ovarian Cancer,” MLO: Medical Laboratory Observer 48, no. 10 (2016): 36–37.

[154] S. Balasubramaniam, J. A. Beaver, S. Horton, et al., “FDA Approval Summary: Rucaparib for the Treatment of Patients With Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 23, no. 23 (2017): 7165–7170.

[155] J. Sus, J. Bosak, and T. Hauser, “Crushing Tablets or Sprinkling Capsules: Implications for Clinical Strategy and Study Performance Based on BE Studies of Rivaroxaban and Deferasirox,” Clinical and Translational Science 17, no. 3 (2024): e13752.

[156] A. Tracy, J. Kahn, B. Geng, et al., “A Novel Case of Chronic Spontaneous Urticaria Associated Chronic Myelogenous Leukemia With Rapid Resolution Upon Treatment With Imatinib,” JAAD Case Rep 30 (2022): 21–23.

[157] D. P. Dash and D. Dinauer, “FDA Cleared Companion Diagnostics (CDx) Tests (IDH1, IDH2 and FLT3) for Acute Myeloid Leukemia (AML) Patient Care,” Blood 138 (2021): 4442.

[158] J. M. Politei and A. Patrono, “Clinically Meaningful Outcomes After 1 Year of Treatment With Setmelanotide in an Adult Patient With a Variant in SH2B1,” Obes Facts 17, no. 6 (2024): 646–651.

[159] S. Souchelnytskyi and N. Souchelnytskyi, “Chloroquine Use in the Treatment of COVID-19: Systems Biology Report of Common Targets of SARS-CoV-2 and Chloroquine,” Research Square (2020). [Preprint].

[160] M. Sandquist and H. R. Wong, “Biomarkers of Sepsis and Their Potential Value in Diagnosis, Prognosis and Treatment,” Expert Review of Clinical Immunology 10, no. 10 (2014): 1349–1356.

[161] B. Wang, X. Zhang, H. Chen, et al., “A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics,” Frontiers in Pharmacology 13 (2022): 859951.

[162] K. Timmerman, M. Weekes, G. Traversy, et al., “Evidence for Optimal HIV Screening and Testing Intervals in HIV-negative Individuals From Various Risk Groups: A Systematic Review,” Canada Communicable Disease Report = Releve des maladies transmissibles au Canada 44, no. 12 (2018): 337–347.

[163] M. L. Bolognesi, A. Gandini, F. Prati, et al., “From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease?,” Journal of Medicinal Chemistry 59, no. 17 (2016): 7759–7770.

[164] D. K. Tripathi, K. Srivastava, K. L. Nagpal, et al., “Exploration of some New Secretory Proteins to Be Employed for Companion Diagnosis of Mycobacterium Tuberculosis,” Immunology Letters 209 (2019): 67–74.

[165] R. B. Stricker and L. Johnson, “Lyme Disease: The Promise of Big Data, Companion Diagnostics and Precision Medicine,” Infection and Drug Resistance 9 (2016): 215–219.

[166] M. Ruhwald, L. de Thurah, D. Kuchaka, et al., “Introducing the ESAT-6 Free IGRA, a Companion Diagnostic for TB Vaccines Based on ESAT-6,” Scientific Reports 7 (2017): 45969.

[167] K. Kasuno, J. Yodoi, and M. Iwano, “Urinary Thioredoxin as a Biomarker of Renal Redox Dysregulation and a Companion Diagnostic to Identify Responders to Redox-Modulating Therapeutics,” Antioxidants & Redox Signaling 36, no. 13-15 (2022): 1051–1065.

[168] H. Matsumoto, “Serum Periostin: A Novel Biomarker for Asthma Management,” Allergology International: Official Journal of the Japanese Society of Allergology 63, no. 2 (2014): 153–160.

[169] R. He, P. Qi, L. Shu, et al., “Dysbiosis and Extraintestinal Cancers,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 44.

[170] D. Krupka, K. Rakoczy, A. Chełmoński, et al., “Crucial Role of Early Detection in Managing Heart Failure in Kearns-Sayre Syndrome: A Case Report,” Am J Case Rep 26 (2025): e947439.

[171] J. Zhong, Y. Liu, N. Luo, et al., “Metagenomic Next-generation Sequencing for Rapid Detection of Pulmonary Infection in Patients With Acquired Immunodeficiency Syndrome,” Ann Clin Microbiol Antimicrob 22, no. 1 (2023): 57.

[172] S. R. Vitale, F. H. Groenendijk, R. van Marion, et al., “TP53 Mutations in Serum Circulating Cell-Free Tumor DNA as Longitudinal Biomarker for High-Grade Serous Ovarian Cancer,” Biomolecules 10, no. 3 (2020): 415.

[173] S. Bernardi, A. Cavalleri, S. Mutti, et al., “Digital PCR (dPCR) Is Able to Anticipate the Achievement of Stable Deep Molecular Response in Adult Chronic Myeloid Leukemia Patients: Results of the DEMONSTRATE Study,” Annal of Hematology 104, no. 1 (2025): 207–217.

[174] M. Fontanilles, F. Marguet, P. Ruminy, et al., “Simultaneous Detection of EGFR Amplification and EGFRvIII Variant Using Digital PCR-based Method in Glioblastoma,” Acta Neuropathol Commun 8, no. 1 (2020): 52.

[175] L. F. Leite da Silva, E. F. Saldanha, and J. S. A. de Menezes, “Plasma ctDNA Kinetics as a Predictor of Systemic Therapy Response for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis,” The Oncologist 30, no. 2 (2025): oyae344.

[176] E. Lin, J. Chien, F. S. Ong, et al., “Challenges and Opportunities for Next-generation Sequencing in Companion Diagnostics,” Expert Review of Molecular Diagnostics 15, no. 2 (2015): 193–209.

[177] J. D. Khoury and D. V. Catenacci, “Next-generation Companion Diagnostics: Promises, Challenges, and Solutions,” Archives of Pathology & Laboratory Medicine 139, no. 1 (2015): 11–13.

[178] G. J. Doherty, M. Petruzzelli, E. Beddowes, et al., “Cancer Treatment in the Genomic Era,” Annual Review of Biochemistry 88 (2019): 247–280.

[179] K. Kato, J. Okami, H. Nakamura, et al., “Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics,” Diagnostics (Basel) 13, no. 8 (2023): 1476.

[180] V. Schacht and J. S. Kern, “Basics of Immunohistochemistry,” The Journal of Investigative Dermatology 135, no. 3 (2015): 1–4.

[181] A. K. Attuluri, C. P. V. Serkad, A. Gunda, et al., “Analytical Validation of CanAssist-Breast: An Immunohistochemistry Based Prognostic Test for Hormone Receptor Positive Breast Cancer Patients,” BMC Cancer 19, no. 1 (2019): 249.

[182] C. Roach, N. Zhang, E. Corigliano, et al., “Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer,” Applied Immunohistochemistry & Molecular Morphology: AIMM 24, no. 6 (2016): 392–397.

[183] T. Neuman, M. London, and J. Kania-Almog, “A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform,” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11, no. 11 (2016): 1863–1868.

[184] J. D. Twomey and B. Zhang, “Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics,” The AAPS Journal 23, no. 2 (2021): 39.

[185] E. Torlakovic, H. J. Lim, J. Adam, et al., ““Interchangeability” of PD-L1 Immunohistochemistry Assays: A Meta-analysis of Diagnostic Accuracy,” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 33, no. 1 (2020): 4–17.

[186] A. I. Fernandez, P. Gaule, and D. L. Rimm, “Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test,” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 36, no. 7 (2023): 100159.

[187] J. T. Jørgensen and M. Hersom, “Companion Diagnostics-a Tool to Improve Pharmacotherapy,” Annals of Translational Medicine 4, no. 24 (2016): 482.

[188] E. Dennis, P. Banks, L. B. Murata, et al., “Validation of an Electronic Program for Pathologist Training in the Interpretation of a Complex Companion Diagnostic Immunohistochemical Assay,” Human Pathology 56 (2016): 194–203.

[189] J. M. Monné Rodríguez, A. L. Frisk, and R. Kreutzer, “European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of in Situ Hybridization Techniques for Drug Research and Development,” Toxicologic Pathology 51, no. 3 (2023): 92–111.

[190] H. Kim and J. H. Chung, “Biomarker Testing of Cytology Specimens in Personalized Medicine for Lung Cancer Patients,” J Pathol Transl Med 56, no. 6 (2022): 326–333.

[191] M. Wu, S. Yuan, K. Liu, et al., “Gastric Cancer Signaling Pathways and Therapeutic Applications,” Technology in Cancer Research & Treatment 23 (2024): 15330338241271935.

[192] S. N. Lone, S. Nisar, T. Masoodi, et al., “Liquid Biopsy: A Step Closer to Transform Diagnosis, Prognosis and Future of Cancer Treatments,” Molecular Cancer 21, no. 1 (2022): 79.

[193] Y. Sato, “Clinical Utility of Liquid Biopsy-based Companion Diagnostics in the Non-small-cell Lung Cancer Treatment,” Exploration of Targeted Anti-Tumor Therapy 3, no. 5 (2022): 630–642.

[194] S. Mirza, K. Bhadresha, M. J. Mughal, et al., “Liquid Biopsy Approaches and Immunotherapy in Colorectal Cancer for Precision Medicine: Are We There Yet?,” Frontiers in Oncology 12 (2022): 1023565.

[195] M. Ignatiadis, G. W. Sledge, and S. S. Jeffrey, “Liquid Biopsy Enters the Clinic—Implementation Issues and Future Challenges,” Nature Reviews Clinical Oncology 18, no. 5 (2021): 297–312.

[196] M. Harigopal, D. Kowalski, and A. Vosoughi, “Enumeration and Molecular Characterization of Circulating Tumor Cells as an Innovative Tool for Companion Diagnostics in Breast Cancer,” Expert review of Molecular Diagnostics 20, no. 8 (2020): 815–828.

[197] A. Morabito and C. Rolfo, “Small Cell Lung Cancer: A New Era Is Beginning?,” Cancers (Basel) 13, no. 11 (2021): 2646.

[198] M. E. Menyailo, M. S. Tretyakova, and E. V. Denisov, “Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds,” International Journal of Molecular Sciences 21, no. 5 (2020): 1696.

[199] K. T. Jin, X. Y. Chen, H. R. Lan, et al., “Current Progress in the Clinical Use of Circulating Tumor Cells as Prognostic Biomarkers,” Cancer Cytopathology 127, no. 12 (2019): 739–749.

[200] T. Rossi, G. Gallerani, G. Martinelli, et al., “Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue,” Biomedicines 9, no. 9 (2021): 1242.

[201] B. Tomasik, M. Skrzypski, M. Bieńkowski, et al., “Current and Future Applications of Liquid Biopsy in Non-small-cell Lung Cancer-A Narrative Review,” Translational Lung Cancer Research 12, no. 3 (2023): 594–614.

[202] I. Casanova-Salas, A. Athie, P. C. Boutros, et al., “Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer,” European Urology 79, no. 6 (2021): 762–771.

[203] K. Das, M. Paltani, P. K. Tripathi, et al., “Current Implications and Challenges of Artificial Intelligence Technologies in Therapeutic Intervention of Colorectal Cancer,” Exploration of Targeted Anti-Tumor Therapy 4, no. 6 (2023): 1286–1300.

[204] A. Stenzinger, V. Endris, J. Budczies, et al., “Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study,” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 15, no. 7 (2020): 1177–1189.

[205] K. Shigeyasu, H. Tazawa, Y. Hashimoto, et al., “Fluorescence Virus-guided Capturing System of Human Colorectal Circulating Tumour Cells for Non-invasive Companion Diagnostics,” Gut 64, no. 4 (2015): 627–635.

[206] S. Nagrath, L. V. Sequist, S. Maheswaran, et al., “Isolation of Rare Circulating Tumour Cells in Cancer Patients by Microchip Technology,” Nature 450, no. 7173 (2007): 1235–1239.

[207] Y. Y. Huang, P. Chen, C. H. Wu, et al., “Screening and Molecular Analysis of Single Circulating Tumor Cells Using Micromagnet Array,” Scientific Reports 5 (2015): 16047.

[208] Y. Q. Li, B. K. Chandran, C. T. Lim, et al., “Rational Design of Materials Interface for Efficient Capture of Circulating Tumor Cells,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 2, no. 11 (2015): 1500118.

[209] D. B. Asante, L. Calapre, M. Ziman, et al., “Liquid Biopsy in Ovarian Cancer Using Circulating Tumor DNA and Cells: Ready for Prime Time?,” Cancer Letters 468 (2020): 59–71.

[210] V. Haselmann, C. Gebhardt, I. Brechtel, et al., “Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy,” Clinical Chemistry 64, no. 5 (2018): 830–842.

[211] R. Yin, Q. Zhang, S. Liao, et al., “Medical Imaging-based Companion Diagnostics for Solid Tumors,” EngMedicine 1, no. 1 (2024): 100009.

[212] J. Schwenck, D. Sonanini, J. M. Cotton, et al., “Advances in PET Imaging of Cancer,” Nature Reviews Cancer 23, no. 7 (2023): 474–490.

[213] S. P. Rowe and M. G. Pomper, “Molecular Imaging in Oncology: Current Impact and Future Directions,” CA: A Cancer Journal for Clinicians 72, no. 4 (2022): 333–352.

[214] E. K. Alexander and E. S. Cibas, “Diagnosis of Thyroid Nodules,” The Lancet Diabetes & Endocrinology 10, no. 7 (2022): 533–539.

[215] Y. Gao, C. Hernandez, H. X. Yuan, et al., “Ultrasound Molecular Imaging of Ovarian Cancer With CA-125 Targeted Nanobubble Contrast Agents,” Nanomedicine: Nanotechnology, Biology, And Medicine 13, no. 7 (2017): 2159–2168.

[216] Z. Dong, P. Liang, G. Guan, et al., “Overcoming Hypoxia-Induced Ferroptosis Resistance via a ¹⁹F/¹H-MRI Traceable Core-Shell Nanostructure,” Angewandte Chemie (International ed in English) 61, no. 48 (2022): e202206074.

[217] L. Succony, D. M. Rassl, A. P. Barker, et al., “Adenocarcinoma Spectrum Lesions of the Lung: Detection, Pathology and Treatment Strategies,” Cancer Treatment Reviews 99 (2021): 102237.

[218] X. Cheng, Y. Chai, J. Xu, et al., “Enzyme Cascade Reaction-based Ratiometric Fluorescence Probe for Visual Monitoring the Activity of Alkaline Phosphatase,” Sensors and Actuators B: Chemical 309 (2020): 127765.

[219] M. Yassin, A. T. Soliman, V. De Sanctis, et al., “A Young Adult With Unintended Acute Intravenous Iron Intoxication Treated With Oral Chelation: The Use of Liver Ferriscan for Diagnosing and Monitoring Tissue Iron Load,” Mediterr J Hematol Infect Dis 9, no. 1 (2017): e2017008.

[220] J. C. Wood, S. Pressel, Z. R. Rogers, et al., “Liver Iron Concentration Measurements by MRI in Chronically Transfused Children With Sickle Cell Anemia: Baseline Results From the TWiTCH Trial,” American Journal of Hematology 90, no. 9 (2015): 806–810.

[221] R. Yue, Z. Li, H. Liu, et al., “Imaging-guided Companion Diagnostics in Radiotherapy by Monitoring APE1 Activity With Afterglow and MRI Imaging,” Nature Communications 15, no. 1 (2024): 6349.

[222] B. V. Marquez-Nostra, S. Lee, R. Laforest, et al., “Preclinical PET Imaging of Glycoprotein Non-metastatic Melanoma B in Triple Negative Breast Cancer: Feasibility of an Antibody-based Companion Diagnostic Agent,” Oncotarget 8, no. 61 (2017): 104303–104314.

[223] X. Pan, Q. Wu, Y. Zhang, et al., “Development and Preclinical Evaluation of CDH17-Specific ImmunoPET Imaging in Colorectal Cancers,” Mol Pharm 22, no. 9 (2025): 5512–5522.

[224] W. Huang, Y. Zhang, M. Cao, et al., “ImmunoPET Imaging of TROP2 in Patients With Solid Tumours,” EMBO Molecular Medicine 16, no. 5 (2024): 1143–1161.

[225] W. Huang, T. Wang, Y. Qiu, et al., “CD38-specific ImmunoPET Imaging for Multiple Myeloma Diagnosis and Therapeutic Monitoring: Preclinical and First-in-human Studies,” European Journal of Nuclear Medicine and Molecular Imaging 52, no. 5 (2025): 1791–1804.

[226] N. C. Wong, Y. Cai, L. K. Meszaros, et al., “Preclinical Development and Characterisation of ⁹⁹Tc-NM-01 for SPECT/CT Imaging of human PD-L1,” Am J Nucl Med Mol Imaging 11, no. 3 (2021): 154–166.

[227] R. A. Rissman, M. C. Donohue, O. Langford, et al., “Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease,” J Prev Alzheimers Dis 11, no. 4 (2024): 823–830.

[228] S. Stacchiotti, S. Martini, S. Pasquali, et al., “GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus Through ATF4/ATF5 Suppression,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 30, no. 22 (2024): 5122–5137.

[229] J. Sebastiano, S. A. McGlone, Z. V. Samuels, et al., “Evaluating Radiotheranostic Targets for Endometrial Cancer,” Journal of Nuclear Medicine 66, no. 10 (2025): 1631–1638.

[230] M. Zhou, B. Chen, C. Lu, et al., “ImmunoPET Imaging of LAG-3 Expression in Tumor Microenvironment With ⁶⁸Ga-labelled Cyclic Peptides Tracers: From Bench to Bedside,” Journal for Immunotherapy of Cancer 12, no. 7 (2024): e009153.

[231] Y. Meng, J. Sun, N. Qv, et al., “Application of Molecular Imaging Technology in Tumor Immunotherapy,” Cellular Immunology 348 (2020): 104039.

[232] K. M. Tully, N. B. Sobol, P. M. R. Pereira, et al. Chapter 10 - Molecular Imaging Companion Diagnostics. in Companion and Complementary Diagnostics, ed. J. T. Jørgensen (Academic Press, 2019): 201–228.

[233] D. Locke and C. C. Hoyt, “Companion Diagnostic Requirements for Spatial Biology Using Multiplex Immunofluorescence and Multispectral Imaging,” Frontiers in Molecular Biosciences 10 (2023): 1051491.

[234] R. L. Van Heertum, R. Scarimbolo, R. Ford, et al., “Companion Diagnostics and Molecular Imaging-enhanced Approaches for Oncology Clinical Trials,” Drug Design, Development and Therapy 9 (2015): 5215–5223.

[235] D. S. Lee and G. J. Cheon, “Nuclear Theranostics in Asia: In Vivo Companion Diagnostics,” Nuclear Medicine and Molecular Imaging 53, no. 1 (2019): 1–6.

[236] K. Mishiro, R. Nishii, I. Sawazaki, et al., “Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib,” Journal of Medicinal Chemistry 65, no. 3 (2022): 1835–1847.

[237] Y. Zeng, T. Dou, L. Ma, et al., “Biomedical Photoacoustic Imaging for Molecular Detection and Disease Diagnosis: , “Always-On” and , “Turn-On” Probes,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 9, no. 25 (2022): e2202384.

[238] M. Y. Lucero and J. Chan, “Photoacoustic Imaging of Elevated Glutathione in Models of Lung Cancer for Companion Diagnostic Applications,” Nature Chemistry 13, no. 12 (2021): 1248–1256.

[239] J. Wischhusen, K. E. Wilson, J. G. Delcros, et al., “Ultrasound Molecular Imaging as a Non-invasive Companion Diagnostic for Netrin-1 Interference Therapy in Breast Cancer,” Theranostics 8, no. 18 (2018): 5126–5142.

[240] A. W. Woodham, S. H. Zeigler, E. L. Zeyang, et al., “In Vivo Detection of Antigen-specific CD8⁺ T Cells by Immuno-positron Emission Tomography,” Nature Methods 17, no. 10 (2020): 1025–1032.

[241] B. N. McKnight and N. T. Viola-Villegas, “⁸⁹Zr-ImmunoPET Companion Diagnostics and Their Impact in Clinical Drug Development,” Journal of Labelled Compounds & Radiopharmaceuticals 61, no. 9 (2018): 727–738.

[242] K. S. Carmon and A. Azhdarinia, “Application of Immuno-PET in Antibody-Drug Conjugate Development,” Molecular Imaging 17 (2018): 1536012118801223.

[243] O. Ilovich, A. Natarajan, S. Hori, et al., “Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope,” Radiology 276, no. 1 (2015): 191–198.

[244] M. Loft, C. Christensen, M. M. Clausen, et al., “First-in-Humans PET Imaging of Tissue Factor in Patients With Primary and Metastatic Cancers Using ¹⁸F-labeled Active-Site Inhibited Factor VII (¹⁸F-ASIS): Potential as Companion Diagnostic,” Journal of Nuclear Medicine 63, no. 12 (2022): 1871–1879.

[245] V. A. Naumenko, S. S. Vodopyanov, K. Y. Vlasova, et al., “Intravital Imaging of Liposome Behavior Upon Repeated Administration: A Step towards the Development of Liposomal Companion Diagnostic for Cancer Nanotherapy,” Journal of Controlled Release: Official Journal of the Controlled Release Society 330 (2021): 244–256.

[246] A. D. Puranik, H. R. Kulkarni, and R. P. Baum, “Companion Diagnostics and Molecular Imaging,” Cancer Journal (Sudbury, Mass) 21, no. 3 (2015): 213–217.

[247] J. M. Idée, S. Louguet, S. Ballet, et al., “Theranostics and Contrast-agents for Medical Imaging: A Pharmaceutical Company Viewpoint,” Quantitative Imaging in Medicine and Surgery 3, no. 6 (2013): 292–297.

[248] D. Gao, X. Guo, Y. Yang, et al., “Microfluidic Chip and Isothermal Amplification Technologies for the Detection of Pathogenic Nucleic Acid,” Journal of Biological Engineering 16, no. 1 (2022): 33.

[249] T. H. M. Moore, S. Dawson, K. Kirby, et al., “Point-of-care Tests in the Emergency Medical Services: A Scoping Review,” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 33, no. 1 (2025): 18.

[250] U. P. Rohr, C. Binder, T. Dieterle, et al., “The Value of in Vitro Diagnostic Testing in Medical Practice: A Status Report,” PLoS ONE 11, no. 3 (2016): e0149856.

[251] S. B. Haga, “Challenges of Development and Implementation of Point of Care Pharmacogenetic Testing,” Expert review of Molecular Diagnostics 16, no. 9 (2016): 949–960.

[252] B. T. Velayudhan and H. K. Naikare, “Point-of-care Testing in Companion and Food Animal Disease Diagnostics,” Frontiers in Veterinary Science 9 (2022): 1056440.

[253] S. Choi, “Powering Point-of-care Diagnostic Devices,” Biotechnology Advances 34, no. 3 (2016): 321–330.

[254] G. A. Aleku, M. P. Adoga, and S. M. Agwale, “HIV Point-of-care Diagnostics: Meeting the Special Needs of sub-Saharan Africa,” Journal of Infection in Developing Countries 8, no. 10 (2014): 1231–1243.

[255] E. M. Abdel-Moety, A. M. Abou Al-Alamein, and E. Fawaz, “A Companion Diagnostic for Personalizing Mivacurium at the Point-of-Care,” Journal of the Electrochemical Society 167, no. 8 (2020): 087510.

[256] J. Aidoo-Brown, D. Moschou, and P. Estrela, “Multiplexed Prostate Cancer Companion Diagnostic Devices,” Sensors (Basel, Switzerland) 21, no. 15 (2021): 5023.

[257] A. S. Modak, “Point-of-care Companion Diagnostic Tests for Personalizing Psychiatric Medications: Fulfilling an Unmet Clinical Need,” Journal of Breath Research 12, no. 1 (2017): 017101.

[258] A. Panneer Selvam and S. Prasad, “Companion and Point-of-Care Sensor System for Rapid Multiplexed Detection of a Panel of Infectious Disease Markers,” SLAS Technology 22, no. 3 (2017): 338–347.

[259] A. Guan, Y. Wang, K. S. Phillips, et al., “A Contact-lens-on-a-chip Companion Diagnostic Tool for Personalized Medicine,” Lab on a Chip 16, no. 7 (2016): 1152–1156.

[260] A. L. Vataire, S. Aballéa, and G. Katz, “Economic Impact of a Genomic Companion Diagnostic Test for Breast Cancer Patients in French Private Hospitals,” Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 17, no. 7 (2014): A623.

[261] G. Campbell, “The Role of Statistics in the Design and Analysis of Companion Diagnostic (CDx) Studies,” Biostatistics & Epidemiology 5, no. 2 (2021): 218–231.

[262] Y. Liu, T. Szu-Yu, M. Michael, et al., “Thresholding of a Continuous Companion Diagnostic Test Confident of Efficacy in Targeted Population,” Statistics in Biopharmaceutical Research 8, no. 3 (2016): 325–333.

[263] Y. Li, Y. Gu, and J. Jiang, “Analysis of the Relationship between the Quality of Small Biopsy Specimens of Non-small Cell Lung Cancer and the Mutation Rate of EGFR Gene,” Zhongguo Fei Ai Za Zhi 24, no. 5 (2021): 331–337.

[264] S. A. Turner, J. D. Peterson, J. R. Pettus, et al., “The Pitfalls of Companion Diagnostics: Evaluation of Discordant EGFR Mutation Results From a Clinical Laboratory and a Central Laboratory,” The Journal of Molecular Diagnostics: JMD 18, no. 3 (2016): 331–335.

[265] H. Moulahoum and F. Ghorbanizamani, “The LOD Paradox: When Lower Isn't Always Better in Biosensor Research and Development,” Biosensors and Bioelectronics 264 (2024): 116670.

[266] C. Chen, M. P. Douglas, M. V. Ragavan, et al., “Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis,” Molecular Diagnosis & Therapy 28, no. 5 (2024): 525–536.

[267] S. Cabello-Aguilar, J. A. Vendrell, and J. Solassol, “Real-World Technical Hurdles of ctDNA NGS Analysis: Lessons From Clinical Implementation,” Diseases 13, no. 10 (2025): 312.

[268] C. Fiala and E. P. Diamandis, “Utility of Circulating Tumor DNA in Cancer Diagnostics With Emphasis on Early Detection,” BMC Medicine [Electronic Resource] 16, no. 1 (2018): 166.

[269] M. Li, “Statistical Methods for Clinical Validation of Follow-On Companion Diagnostic Devices via an External Concordance Study,” Statistics in Biopharmaceutical Research 8, no. 3 (2016): 355–363.

[270] L. Ma, H. Guo, Y. Zhao, et al., “Liquid Biopsy in Cancer Current: Status, Challenges and Future Prospects,” Signal Transduct Target Ther 9, no. 1 (2024): 336.

[271] M. Gerlinger, A. J. Rowan, S. Horswell, et al., “Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing,” New England Journal of Medicine 366, no. 10 (2012): 883–892.

[272] J. C. M. Wan, C. Massie, J. Garcia-Corbacho, et al., “Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA,” Nature Reviews Cancer 17, no. 4 (2017): 223–238.

[273] G. Siravegna, S. Marsoni, S. Siena, et al., “Integrating Liquid Biopsies Into the Management of Cancer,” Nature Reviews Clinical Oncology 14, no. 9 (2017): 531–548.

[274] C. Alix-Panabières and K. Pantel, “Clinical Prospects of Liquid Biopsies,” Nature Biomedical Engineering 1, no. 4 (2017): 0065.

[275] N. McGranahan and C. Swanton, “Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future,” Cell 168, no. 4 (2017): 613–628.

[276] I. Dagogo-Jack and A. T. Shaw, “Tumour Heterogeneity and Resistance to Cancer Therapies,” Nature Reviews Clinical Oncology 15, no. 2 (2018): 81–94.

[277] J. F. Graf and M. I. Zavodszky, “Characterizing the Heterogeneity of Tumor Tissues From Spatially Resolved Molecular Measures,” PLoS ONE 12, no. 11 (2017): e0188878.

[278] P. R. Prasetyanti and J. P. Medema, “Intra-tumor Heterogeneity From a Cancer Stem Cell Perspective,” Molecular Cancer 16, no. 1 (2017): 41.

[279] J. Hausser and U. Alon, “Tumour Heterogeneity and the Evolutionary Trade-offs of Cancer,” Nature Reviews Cancer 20, no. 4 (2020): 247–257.

[280] C. Carmona-Fontaine, M. Deforet, L. Akkari, et al., “Metabolic Origins of Spatial Organization in the Tumor Microenvironment,” PNAS 114, no. 11 (2017): 2934–2939.

[281] E. F. Davis-Marcisak, T. D. Sherman, P. Orugunta, et al., “Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data,” Cancer Research 79, no. 19 (2019): 5102–5112.

[282] Y. N. Lamb, “Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC,” Target Oncol 16, no. 5 (2021): 687–695.

[283] J. He, Z. Huang, L. Han, et al., “Mechanisms and Management of 3rd‑Generation EGFR‑TKI Resistance in Advanced Non‑Small Cell Lung Cancer (Review),” International Journal of Oncology 59, no. 5 (2021): 90.

[284] S. Morganti, P. Tarantino, E. Ferraro, et al., “Complexity of Genome Sequencing and Reporting: Next Generation Sequencing (NGS) Technologies and Implementation of Precision Medicine in Real Life,” Critical Reviews in Oncology/Hematology 133 (2019): 171–182.

[285] K. Mishiro, S. Imai, Y. Ematsu, et al., “RGD Peptide-Conjugated Dodecaborate With the Ga-DOTA Complex: A Preliminary Study for the Development of Theranostic Agents for Boron Neutron Capture Therapy and Its Companion Diagnostics,” Journal of Medicinal Chemistry 65, no. 24 (2022): 16741–16753.

[286] D. Luo, J. A. Smith, N. A. Meadows, et al., “A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics,” Frontiers in Genetics 6 (2015): 357.

[287] M. Gomez Montero, H. El Alili, and M. Hashim, “How Are Companion Diagnostics Considered in Economic Evaluations of Oncology Treatments? A Review of Health Technology Assessments,” PharmacoEconomics—Open 6, no. 5 (2022): 637–646.

[288] S. B. Kim, I. H. Song, Y. S. Song, et al., “Biodistribution and Internal Radiation Dosimetry of a Companion Diagnostic Radiopharmaceutical, [⁶⁸Ga]PSMA-11, in Subcutaneous Prostate Cancer Xenograft Model Mice,” Scientific Reports 11, no. 1 (2021): 15263.

[289] B. Doble, M. Tan, A. Harris, et al., “Modeling Companion Diagnostics in Economic Evaluations of Targeted Oncology Therapies: Systematic Review and Methodological Checklist,” Expert Review of Molecular Diagnostics 15, no. 2 (2015): 235–254.

[290] T. A. Barnes, E. Amir, A. J. Templeton, et al., “Efficacy, Safety, Tolerability and Price of Newly Approved Drugs in Solid Tumors,” Cancer Treatment Reviews 56 (2017): 1–7.

[291] J. R. Trosman, S. L. Van Bebber, and K. A. Phillips, “Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-gene Assay,” J Oncol Pract 6, no. 5 (2010): 238–242.

[292] A. Aggarwal, T. Fojo, C. Chamberlain, et al., “Do Patient Access Schemes for High-cost Cancer Drugs Deliver Value to Society?-Lessons From the NHS Cancer Drugs Fund,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 28, no. 8 (2017): 1738–1750.

[293] L. Govaerts, S. Simoens, W. Van Dyck, et al., “Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries,” Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 23, no. 5 (2020): 606–615.

[294] M. R. Trusheim and E. R. Berndt, “The Clinical Benefits, Ethics, and Economics of Stratified Medicine and Companion Diagnostics,” Drug Discovery Today 20, no. 12 (2015): 1439–1450.

[295] B. Quinn, “Payers and the Assessment of Clinical Utility for Companion Diagnostics,” Clinical Pharmacology and Therapeutics 88, no. 6 (2010): 751–754.

[296] S. K. Byron, N. Crabb, E. George, et al., “The Health Technology Assessment of Companion Diagnostics: Experience of NICE,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20, no. 6 (2014): 1469–1476.

[297] L. San Miguel and F. Hulstaert, “The Importance of Test Accuracy in Economic Evaluations of Companion Diagnostics,” Journal of Comparative Effectiveness Research 4, no. 6 (2015): 569–577.

[298] L. Schluckebier, R. Caetano, O. U. Garay, et al., “Cost-effectiveness Analysis Comparing Companion Diagnostic Tests for EGFR, ALK, and ROS1 versus Next-generation Sequencing (NGS) in Advanced Adenocarcinoma Lung Cancer Patients,” BMC Cancer 20, no. 1 (2020): 875.

[299] E. A. Lim, H. Lee, E. Bae, et al., “Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea,” PLoS ONE 11, no. 8 (2016): e0160155.

[300] G. S. Zaric, “Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine,” Pharmacoeconomics 34, no. 7 (2016): 635–644.

[301] D. Horgan, G. Ciliberto, P. Conte, et al., “Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology,” Biomedicine Hub 5, no. 3 (2020): 182–223.

[302] J. Lee and F. Lopez-Rios, “Health Economics and Outcomes Research: Informing Companion Diagnostic Development, Guidelines, Adoption and Reimbursement,” Expert Review of Molecular Diagnostics 13, no. 5 (2013): 413–415.

[303] D. F. Steiner, P. C. Chen, and C. H. Mermel, “Closing the Translation Gap: AI Applications in Digital Pathology,” Biochimica et Biophysica Acta Reviews on Cancer 1875, no. 1 (2021): 188452.

[304] R. Kamla and N. Komori, “Diagnosing the Translation Gap,” Accounting, Auditing & Accountability Journal 31, no. 7 (2018): 1874–1903.

[305] D. Hartl, V. de Luca, A. Kostikova, et al., “Translational Precision Medicine: An Industry Perspective,” Journal of Translational Medicine 19, no. 1 (2021): 245.

[306] H. P. Shih, X. Zhang, and A. M. Aronov, “Drug Discovery Effectiveness From the Standpoint of Therapeutic Mechanisms and Indications,” Nature Reviews Drug Discovery 17, no. 1 (2018): 78.

[307] G. M. Blumenthal, E. Mansfield, and R. Pazdur, “Next-Generation Sequencing in Oncology in the Era of Precision Medicine,” JAMA Oncology 2, no. 1 (2016): 13–14.

[308] R. Salgado, A. M. Bellizzi, D. Rimm, et al., “How Current Assay Approval Policies Are Leading to Unintended Imprecision Medicine,” The Lancet Oncology 21, no. 11 (2020): 1399–1401.

[309] D. M. Roscoe, Y. F. Hu, and R. Philip, “Companion Diagnostics: A Regulatory Perspective From the Last 5 Years of Molecular Companion Diagnostic Approvals,” Expert Review of Molecular Diagnostics 15, no. 7 (2015): 869–880.

[310] M. Ansari, “The Regulation of Companion Diagnostics: A Global Perspective,” Therapeutic Innovation & Regulatory Science 47, no. 4 (2013): 405–415.

[311] S. L. Kang, J. H. Woo, N. H. Kim, et al., “Necessity of Strengthening the Current Clinical Regulatory for Companion Diagnostics: An Institutional Comparison of the FDA, EMA, and MFDS,” Molecular Therapy Methods & Clinical Development 30 (2023): 447–458.

[312] J. T. Jørgensen, “Oncology Drug-companion Diagnostic Combinations,” Cancer Treatment and Research Communications 29 (2021): 100492.

[313] S. W. Karuri and R. Simon, “A Two-stage Bayesian Design for Co-development of New Drugs and Companion Diagnostics,” Statistics in Medicine 31, no. 10 (2012): 901–914.

[314] P. D. Cotter, “A New Paradigm for Personalized Medicine and Companion Diagnostics: The Contract Diagnostics Organization,” The Open Conference Proceedings Journal 3, no. 1 (2012): 52–58.

[315] J. Thomas, E. Stratton, and M. Keppens, “Companion Diagnostics: Emerging Strategies and Issues in Pharmaceutical Development,” Expert Review of Molecular Diagnostics 12, no. 6 (2012): 561–563.

[316] S. H. Ou, R. A. Soo, A. Kubo, et al., “Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?,” Frontiers in Oncology 4 (2014): 58.

[317] J. T. Jørgensen, “Companion Diagnostics and the Drug–Diagnostic Codevelopment Model,” Drug Development Research 73, no. 7 (2012): 390–397.

[318] J. T. Jørgensen and M. Hersom, “Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology,” Clinical Pharmacology and Therapeutics 103, no. 6 (2018): 999–1008.

[319] J. A. Beaver, A. Tzou, G. M. Blumenthal, et al., “An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 23, no. 6 (2017): 1368–1372.

[320] C. Ensinger, “Models of Partnership Between the Pharmaceutical and Diagnostics Industries Around Companion Diagnostics for Cancer and Beyond,” Expert Opinion on Medical Diagnostics 5, no. 2 (2011): 91–94.

[321] R. Bijker, S. S. Merkouris, N. A. Dowling, et al., “ChatGPT for Automated Qualitative Research: Content Analysis,” Journal of Medical Internet Research 26 (2024): e59050.

[322] A. K. Sah, D. S. Rao, A. M. Abbas, et al., “The Future of Diagnostics: Cutting-edge Advances in Healthcare Technology,” Italian Journal of Medicine 19, no. 2 (2025). n.p.

[323] D. Amodio, C. Rossetti, A. Angelidou, et al., “Immune Development in Early Life (IDEaL) Longitudinal Cohort Study Protocol: Identifying Biomarkers of Vaccine Responsiveness, Respiratory Infection, and Asthma,” J Allergy Clin Immunol Glob 4, no. 4 (2025): 100517.

[324] Y. Yoshinaga, C. Daum, G. He, et al., “Genome Sequencing,” Methods in Molecular Biology 1775 (2018): 37–52.

[325] S. A. Mahoney, A. K. Dey, N. Basisty, et al., “Identification and Functional Analysis of Senescent Cells in the Cardiovascular System Using Omics Approaches,” American Journal of Physiology. Heart and Circulatory Physiology 325, no. 5 (2023): H1039–H1058.

[326] R. Aebersold and M. Mann, “Mass-spectrometric Exploration of Proteome Structure and Function,” Nature 537, no. 7620 (2016): 347–355.

[327] L. Cui, H. Lu, and Y. H. Lee, “Challenges and Emergent Solutions for LC-MS/MS Based Untargeted Metabolomics in Diseases,” Mass Spectrometry Reviews 37, no. 6 (2018): 772–792.

[328] A. D. Kennedy, M. J. Miller, K. Beebe, et al., “Metabolomic Profiling of Human Urine as a Screen for Multiple Inborn Errors of Metabolism,” Genetic Testing and Molecular Biomarkers 20, no. 9 (2016): 485–495.

[329] V. Tolstikov, V. R. Akmaev, R. Sarangarajan, et al., “Clinical Metabolomics: A Pivotal Tool for Companion Diagnostic Development and Precision Medicine,” Expert Review of Molecular Diagnostics 17, no. 5 (2017): 411–413.

[330] W. Zhang, Z. Cai, D. Liang, et al., “Immune Cell-Related Genes in Juvenile Idiopathic Arthritis Identified Using Transcriptomic and Single-Cell Sequencing Data,” International Journal of Molecular Sciences 24, no. 13 (2023): 10619.

[331] I. Zafar, A. Unar, N. U. Khan, et al., “Molecular Biology in the Exabyte Era: Taming the Data Deluge for Biological Revelation and Clinical Transformation,” Computational Biology and Chemistry 119 (2025): 108535.

[332] J. Zhang, W. Wang, and X. Q. Wang, “A Robust Diagnostic Model for High-risk MASH: Integrating Clinical Parameters and Circulating Biomarkers through a Multi-omics Approach,” Hepatology International 19, no. 4 (2025): 820–835.

[333] P. Wang, S. Liang, H. Zhang, et al., “Molecular Characterization of Breast Cancer and Multiple Primary Malignancies: The Latest Application Using Unmarked Quantitative Proteomics,” Int J Surg 111, no. 11 (2025): 7746–7760.

[334] A. K. Sah, M. Afzal, R. H. Elshaikh, et al., “Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes,” Life (Basel) 15, no. 5 (2025): 779.

[335] M. M. Alruwaili, F. H. Abuadas, M. Alsadi, et al., “Exploring Nurses' Awareness and Attitudes Toward Artificial Intelligence: Implications for Nursing Practice,” Digit Health 10 (2024): 20552076241271803.

[336] P. Leo, A. Janowczyk, R. Elliott, et al., “Computer Extracted Gland Features From H&E Predicts Prostate Cancer Recurrence Comparably to a Genomic Companion Diagnostic Test: A Large Multi-site Study,” NPJ Precision Oncology 5, no. 1 (2021): 35.

[337] A. Babker, R. S. Suliman, A. A. M. Ghazwani, W. AlHarbi, and V. Lyashenko, “Combined Use of Edge Selection Operators in Individual Color Channels for the Analysis of Cytological Images Presented in RGB Format,” Biomedical and Pharmacology Journal 18 (2025): 121–138.

[338] M. S. Nabi, M. F. A. Fauzi, Z. U. Rehman, et al., “HER2-IHC-40x: A High-resolution Histopathology Dataset for HER2 IHC Scoring in Breast Cancer,” Data Brief 62 (2025): 111922.

[339] G. Ye, Z. Wei, C. Han, et al., “AI-derived Longitudinal and Multi-dimensional CT Classifier for Non-small Cell Lung Cancer to Optimize Neoadjuvant Chemoimmunotherapy Decision: A Multicentre Retrospective Study,” EClinicalMedicine 89 (2025): 103551.

[340] Roche. Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer 2025, https://www.roche.com/media/releases/med-cor-2025-04-29?utm_source=chatgpt.com.

[341] J. Clough, M. Colwill, A. Poullis, et al., “Biomarkers in Inflammatory Bowel Disease: A Practical Guide,” Therap Adv Gastroenterol 17 (2024): 17562848241251600.

[342] P. Wu, C. Zhang, X. Tang, et al., “Pan-cancer Characterization of Cell-free Immune-related miRNA Identified as a Robust Biomarker for Cancer Diagnosis,” Molecular Cancer 23, no. 1 (2024): 31.

[343] C. Ladbury, A. Amini, A. Govindarajan, et al., “Integration of Artificial Intelligence in Lung Cancer: Rise of the Machine,” Cell Reports Medicine 4, no. 2 (2023): 100933.

[344] P. X. Wang, Y. C. Zhong, B. Duan, et al., “Exploring Morphological Heterogeneity of Circulating Tumor Cells: Machine Learning-based Approach for Cell Identification and Prognostic Implications,” Science Bulletin (Beijing) 70, no. 13 (2025): 2070–2074.

[345] K. Swanson, E. Wu, A. Zhang, et al., “From Patterns to Patients: Advances in Clinical Machine Learning for Cancer Diagnosis, Prognosis, and Treatment,” Cell 186, no. 8 (2023): 1772–1791.

[346] A. K. Sah, R. H. Elshaikh, M. G. Shalabi, et al., “Role of Artificial Intelligence and Personalized Medicine in Enhancing HIV Management and Treatment Outcomes,” Life (Basel) 15, no. 5 (2025): 745.

[347] M. Li, Y. Wu, and J. Lin, “Imaging-guided Companion Theranostics: Ushering in a New Era of Personalized Cancer Care,” Nano Biomedicine and Engineering 17, no. 1 (2025): 3–16.

[348] G. Gebhart, L. E. Lamberts, Z. Wimana, et al., “Molecular Imaging as a Tool to Investigate Heterogeneity of Advanced HER2-positive Breast Cancer and to Predict Patient Outcome Under Trastuzumab Emtansine (T-DM1): The ZEPHIR Trial,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 27, no. 4 (2016): 619–624.

[349] X. Shen, H. Zhou, X. Zhou, et al., “(68)Ga-grazytracer PET for Noninvasive Assessment of Response to Immunotherapy in Solid Tumors and Lymphomas: A Phase 1/2 Clinical Trial,” Nature Communications 15, no. 1 (2024): 8791.

[350] B. Li, H. Liu, Y. He, et al., “A , “Self-Checking” pH/Viscosity-Activatable NIR-II Molecule for Real-Time Evaluation of Photothermal Therapy Efficacy,” Angewandte Chemie (International ed in English) 61, no. 16 (2022): e202200025.

[351] R. Woodhouse, M. Li, J. Hughes, et al., “Clinical and Analytical Validation of FoundationOne Liquid CDx, a Novel 324-Gene cfDNA-based Comprehensive Genomic Profiling Assay for Cancers of Solid Tumor Origin,” PLoS ONE 15, no. 9 (2020): e0237802.

[352] S. Ando, S. Futami, K. Azuma, et al., “Synchronous Double Primary Lung Adenocarcinomas with EGFR L858R Point Mutation and MET Exon 14 Skipping Mutation,” Journal of Medical Cases 15, no. 8 (2024): 153–158.

[353] M. Wang, Y. Fan, M. Sun, et al., “Sunvozertinib for Patients in China With Platinum-pretreated Locally Advanced or Metastatic Non-small-cell Lung Cancer and EGFR Exon 20 Insertion Mutation (WU-KONG6): Single-arm, Open-label, Multicentre, Phase 2 Trial,” Lancet Respiratory Medicine 12, no. 3 (2024): 217–224.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.